Investment Rating - The investment rating for the company is "Buy" (maintained) [2][9][18] Core Views - The company's Q3 performance was impacted by weak macro demand, but new projects are progressing steadily [2][4] - For the first three quarters of 2024, the company achieved revenue of 147.6 billion yuan, a year-on-year increase of 11.4%, while net profit attributable to shareholders was 11.1 billion yuan, a year-on-year decrease of 12.7% [2][4] - The company is expected to maintain growth with new capacity coming online, enhancing its competitive edge [9][10] Financial Performance Summary - In Q3 2024, the company reported revenue of 50.5 billion yuan, a year-on-year increase of 12.5% but a quarter-on-quarter decrease of 0.7% [3][4] - The net profit for Q3 2024 was 2.92 billion yuan, down 29.4% year-on-year and down 27.3% quarter-on-quarter [3][4] - The operating cash flow for Q3 2024 was 9 billion yuan, an increase of 31 million yuan year-on-year [3][4] - The gross margin for Q3 2024 was 13.4%, down 4.0 percentage points year-on-year [3][4] Segment Performance Summary - The polyurethane segment generated revenue of 18.8 billion yuan in Q3 2024, up 8.5% year-on-year [5] - The petrochemical segment achieved revenue of 22.4 billion yuan, a year-on-year increase of 42.4% [5] - The fine chemicals and new materials segment reported revenue of 7 billion yuan, a year-on-year increase of 10.9% [5] Price Spread Analysis - The average price spread for polymer MDI in Q3 2024 was 10,823 yuan/ton, up 2.5% year-on-year [6] - The average price spread for pure MDI decreased by 21.5% year-on-year to 11,886 yuan/ton [6] - The average price spread for TDI fell by 30.2% year-on-year to 9,243 yuan/ton [6] Future Outlook - The company is expected to achieve revenues of 190.6 billion yuan, 230.5 billion yuan, and 261.8 billion yuan for 2024, 2025, and 2026 respectively [10][18] - The net profit forecast for the same years is 14.9 billion yuan, 20.4 billion yuan, and 25.9 billion yuan respectively [10][18] - The company is projected to maintain a PE ratio of 16, 12, and 9 for the years 2024, 2025, and 2026 respectively [10][18]

2024 年 11 月 01 日 晨会纪要 研究所： 证券分析师： 余春生 S0350513090001 yucs@ghzq.com.cn [Table_Title] 晨会纪要 ——2024 年第 187 期 观点精粹: 最新报告摘要 单三季度营收同比+127%，盈利能力持续改善--安达智能/自动化设备(688125/216407) 科创板公司动态研究 盈利能力同比提升，大家居战略坚定推进--欧派家居/家居用品(603833/213603) 公司点评 销量环比微降，投资增厚业绩--陕西煤业/煤炭开采(601225/217401) 公司点评 2024Q3 主动型基金在煤炭行业持仓比例环比下降 0.36pct，延续低配状态--行业专题研究 三季度扣非归母净利润创历史新高，拟对墨西哥控股子公司增资--赛轮轮胎/汽车零部件(601058/212802) 公 司点评 怎么看财政赤字？--宏观深度研究 Q3 业绩同比提升，下游石化项目迎来进展--博隆技术/专用设备(603325/216402) 中小市值点评报告 征途小游戏推动 24Q3 营收环比增长，积极关注《王者征途》持续表现和《原始征途》版本大推--巨人网络/ 游戏 ...

Investment Rating - The investment rating for the company is "Accumulate" (maintained) [1][6]. Core Views - The company's Q3 performance shows a year-on-year improvement, with revenue from downstream petrochemical projects increasing due to better acceptance progress and confirmed orders [2][5]. - The company reported a total revenue of 581 million yuan for the first three quarters of 2024, a decrease of 23.52% year-on-year, while the net profit attributable to shareholders was 169 million yuan, down 4.45% year-on-year. However, Q3 revenue reached 214 million yuan, an increase of 9.25% year-on-year, and net profit attributable to shareholders was 71 million yuan, up 60.20% year-on-year [1][2]. - The company has a high level of contract liabilities, amounting to 2.444 billion yuan as of September 30, 2024, which provides assurance for future performance as downstream projects are gradually accepted and revenue is confirmed [2][5]. - The company maintains good liquidity and cash flow, with a cash balance of 668 million yuan and a net cash flow from operating activities of 445 million yuan for the first three quarters of 2024 [2][5]. Summary by Sections Financial Performance - For Q3 2024, the company achieved a gross margin of 41.54%, an increase of 6.67 percentage points year-on-year, and a net margin of 33.14%, up 10.54 percentage points year-on-year, marking historical highs for both metrics [3][6]. - The comprehensive gross margin for the first three quarters of 2024 was 34.31%, up 1.84 percentage points year-on-year, while the net margin was 29.14%, an increase of 5.82 percentage points year-on-year [3][6]. Revenue and Profit Forecast - The company is expected to generate revenues of 1.303 billion yuan, 2.225 billion yuan, and 2.730 billion yuan for the years 2024, 2025, and 2026, respectively, with corresponding net profits of 296 million yuan, 475 million yuan, and 566 million yuan [6][7]. - The projected P/E ratios for 2024, 2025, and 2026 are 16, 10, and 8 times, respectively, indicating a favorable valuation outlook [6][7]. Market Trends - The acceleration of large-scale integrated refining and chemical projects, such as the Yulong Island project, is expected to benefit the demand for large-scale equipment in the upstream sector [5][6]. - The company’s products are integral to key projects like Yulong and Baofeng, which are expected to enhance the revenue recognition pace as these projects progress [5][6].

2024 年 10 月 31 日 公司研究 评级：买入(维持) 研究所： 证券分析师： 戴畅 S0350523120004 daic@ghzq.com.cn 证券分析师： 吴铭杰 S0350524090003 wumj@ghzq.com.cn [Table_Title] 2024 年 Q3 归母净利润同比稳中有升，机器人 执行器有望打造第三成长曲线 ——三花智控（002050）2024 年 Q3 季报点评 最近一年走势 事件: 2024 年 10 月 30 日，三花智控发布 2024 年 Q3 季报：2024 年 Q1-Q3 公司实现营收 205.63 亿元，同比+8.4%；归母净利润 23.02 亿元，同比 +6.6%；扣非后归母净利润 22.48 亿元，同比+1.1%，其中 2024Q3 实现 营收 68.87 亿元，同比+6.8%；归母净利润 7.87 亿元，同比+3%；扣非 后归母净利润 7.21 亿元，同比-4.5%。 投资要点: 相对沪深 300 表现 2024/10/30 2024 年 Q3 归母净利润同比稳中有升，毛利率环比提升。 2024 年 Q3 公司实现归母净利润 7.87 亿元，同比+ ...

Investment Rating - The report maintains a "Buy" rating for the company [2][8] Core Views - The company's revenue for the first three quarters of 2024 reached 5.513 billion yuan, a year-on-year increase of 13.81%, while the net profit attributable to shareholders was 2.006 billion yuan, up 20.19% year-on-year [2] - In Q3 2024, the company reported revenue of 1.711 billion yuan, a year-on-year increase of 2.32%, and a net profit of 625 million yuan, up 2.86% year-on-year [2][3] - The company is experiencing a slowdown in growth rates, particularly in Q3, but continues to see strong performance in its premium product lines, especially the "Dongcang" series [3] Summary by Sections Revenue and Profitability - For Q3 2024, the company achieved revenue of 1.711 billion yuan, with a year-on-year growth of 2.32%, and a net profit of 625 million yuan, reflecting a year-on-year increase of 2.86% [2][3] - The gross profit margin improved to 75.84%, an increase of 2.88 percentage points year-on-year, attributed to product mix upgrades and cost optimization [4] Product and Regional Performance - In Q3 2024, the revenue from mid-to-high-end liquor was 1.296 billion yuan, up 7.12% year-on-year, while ordinary liquor revenue was 336 million yuan, down 9.16% year-on-year [3] - Revenue from Anhui province reached 1.116 billion yuan, a year-on-year increase of 6.85%, while revenue from outside the province was 516 million yuan, down 3.62% year-on-year [3] Future Outlook - The company is expected to continue benefiting from its product positioning in the 100 yuan price range, with the "Dongcang" series likely to sustain growth [6] - Revenue forecasts for 2024-2026 are projected at 7.552 billion yuan, 8.449 billion yuan, and 9.397 billion yuan respectively, with net profits of 2.591 billion yuan, 2.930 billion yuan, and 3.285 billion yuan [6][7]

Investment Rating - The investment rating for the company is "Buy" (maintained) [2][8]. Core Views - The demand for medical devices in China is poised for growth, supported by government policies encouraging equipment upgrades [3]. - The company has experienced short-term revenue pressure, with a projected revenue decline of 4.74% year-on-year for the first three quarters of 2024 [2]. - Despite the short-term challenges, the company is expected to benefit from the implementation of equipment upgrade policies, which could drive future revenue growth [3]. Summary by Sections Financial Performance - For the first three quarters of 2024, the company reported revenue of 1.398 billion yuan, a decrease of 4.74% year-on-year, and a net profit attributable to shareholders of 109 million yuan, down 66.01% year-on-year [2]. - In Q3 2024 alone, the company achieved revenue of 386 million yuan, representing a year-on-year decline of 9.18%, with a net loss of 62 million yuan [2]. Market Outlook - The State Council released a plan to promote large-scale equipment upgrades, which is expected to benefit the medical device market [3]. - The company has launched the "Start New" equipment upgrade program, covering a full range of innovative devices, which is anticipated to enhance its market position [3]. Research and Development - The company has increased its R&D expenditure to 338 million yuan in the first three quarters of 2024, a rise of 28.33% year-on-year, accounting for 24.20% of its revenue [3]. - The company has established seven R&D centers globally, maintaining its core technological advantages [3]. Earnings Forecast - The revenue projections for 2024-2026 are 2.126 billion yuan, 2.597 billion yuan, and 3.193 billion yuan, respectively, with net profits expected to be 253 million yuan, 466 million yuan, and 627 million yuan [6][8]. - The company’s P/E ratios are projected to be 61x, 33x, and 25x for the years 2024, 2025, and 2026, respectively [3][6].

Investment Rating - The report maintains a "Buy" rating for the company [2] Core Views - The company's revenue in Q3 2024 reached 791 million yuan, a year-over-year decrease of 3.94%, but a quarter-over-quarter increase of 8.28%. The net profit attributable to the parent company was 353 million yuan, down 16.18% year-over-year and down 3.34% quarter-over-quarter [3][4] - The gross profit margin for Q3 2024 was 89.81%, an increase of 0.22 percentage points year-over-year [4] - The company is focusing on the performance of its mini-games, particularly the "Wangzhe Zhengtu" and the new version of "Yuanshi Zhengtu," which are expected to drive growth [5][7] Summary by Sections Financial Performance - For Q1-Q3 2024, the company achieved a total revenue of 2.218 billion yuan, a year-over-year decrease of 2.15%. The net profit attributable to the parent company was 1.071 billion yuan, a decrease of 1.29% year-over-year [4] - The company’s operating expenses for Q3 2024 were 2.79 million yuan for sales, 0.50 million yuan for management, and 1.89 million yuan for R&D, with year-over-year increases of 21.99%, 40.36%, and 3.34% respectively [4] Market Position - The company’s stock has performed well relative to the CSI 300 index, with a 1-month performance of 7.5%, 3-month performance of 45.6%, and a 12-month performance of 12.1% [4] - The "Wangzhe Zhengtu" mini-game ranked in the top 10 of the mini-game sales charts for July, August, and September 2024, indicating strong market traction [5] Future Projections - Revenue projections for 2024-2026 are 3.293 billion yuan, 3.639 billion yuan, and 3.926 billion yuan respectively, with net profits projected at 1.456 billion yuan, 1.654 billion yuan, and 1.814 billion yuan [7][8] - The expected EPS for 2024, 2025, and 2026 is 0.75 yuan, 0.86 yuan, and 0.94 yuan respectively, with corresponding P/E ratios of 16.88, 14.85, and 13.54 [8]

Investment Rating - Buy (maintained) [1] Core Views - The company's Q3 performance was under short-term pressure, with revenue of 2.386 billion yuan, a year-on-year decrease of 2.88%, and net profit attributable to the parent company of 574 million yuan, a year-on-year decrease of 13.67% [1] - The company is expected to release its first whiskey product on November 19, which could become a new growth driver given the potential of the domestic whiskey market [2] - Despite short-term challenges, the company's pre-mixed alcohol business remains the market leader with over 80% market share, and its long-term growth potential is still promising [3] Financial Performance - Q3 revenue was 758 million yuan, a year-on-year decrease of 5.95%, with net profit attributable to the parent company of 172 million yuan, a year-on-year decrease of 24.01% [3] - Pre-mixed alcohol revenue for the first three quarters was 2.102 billion yuan, a year-on-year decrease of 3.13%, with Q3 revenue of 671 million yuan, a year-on-year decrease of 6.58% [3] - Gross margin increased by 1.34 percentage points to 70.18% in Q3, benefiting from lower production costs and reduced transportation expenses [3] - Sales expense ratio increased by 3.14 percentage points to 23.46% in Q3 due to increased market investment in a weak consumption environment [3] Industry and Product Analysis - The domestic whiskey market is dominated by high-priced imported brands, but domestic production capacity exceeded imports in 2023 [2] - The company has been preparing for its whiskey business since 2016, with production capacity far exceeding other distilleries, and its whiskey has reached a three-year aging period [2] - The company has innovatively developed whiskey with Chinese flavors, such as yellow wine barrel and Mongolian oak barrel whiskey, and has made significant progress in channel construction and consumer education [2] Future Outlook - Revenue for 2024-2026 is expected to be 3.3/4.0/4.7 billion yuan, with year-on-year growth rates of 1%/21%/18% [4] - Net profit attributable to the parent company for 2024-2026 is expected to be 721/889/1,077 million yuan, with year-on-year growth rates of -11%/23%/21% [4] - The company's pre-mixed alcohol "358" matrix continues to improve, and the upcoming whiskey product is highly anticipated [4] Valuation - The company's P/E ratio for 2024-2026 is expected to be 32/26/21 times, with P/B ratios of 5.53/5.29/5.08 times [6] - ROE for 2024-2026 is forecasted to be 17%/20%/24% [6]

Investment Rating - The report maintains a "Buy" rating for the company [1][13][21] Core Views - The company continues to enhance its titanium ore resource reserves, with a dividend payout ratio of 83.65% in the first three quarters of 2024, balancing shareholder returns with long-term development [1][9] - The average price of titanium dioxide decreased by 1.77% year-on-year and 4.71% quarter-on-quarter, while the average price of titanium concentrate increased by 5.62% year-on-year and 2.02% quarter-on-quarter [5][6] - The company has signed strategic cooperation agreements to improve its supply chain resilience and flexibility, aligning with its core business development strategy [6][9] Financial Performance Summary - For the first three quarters of 2024, the company achieved operating revenue of 20.885 billion yuan, a year-on-year increase of 2.97%, and a net profit attributable to shareholders of 2.564 billion yuan, a year-on-year increase of 19.68% [5][11] - In Q3 2024, the company reported revenue of 7.081 billion yuan, a year-on-year increase of 0.85% and a quarter-on-quarter increase of 8.77% [5][11] - The company’s gross profit margin for Q3 2024 was 25.81%, a decrease of 3.15% year-on-year and 0.87% quarter-on-quarter [5][11] Price and Market Data - As of October 30, 2024, the company's stock price was 19.21 yuan, with a market capitalization of approximately 45.84 billion yuan [3][5] - The company is the largest titanium dioxide producer globally, with an annual production capacity of 1.51 million tons [9][11] Earnings Forecast - The company’s projected operating revenues for 2024, 2025, and 2026 are 28.088 billion yuan, 32.444 billion yuan, and 34.626 billion yuan, respectively, with corresponding net profits of 3.354 billion yuan, 4.128 billion yuan, and 4.634 billion yuan [11][21]

Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [2][4]. Core Views - The company has entered a new development stage following a change in its controlling shareholder, with Haier Biological acquiring a 20% stake [3][4]. - The company reported stable revenue and profit figures for Q3 2024, with a year-on-year revenue increase of 6.39% and a net profit increase of 2.81% for the first three quarters [3][4]. - The report anticipates a steady growth phase for the company, supported by the new controlling shareholder [4]. Financial Performance Summary - For the first three quarters of 2024, the company achieved a revenue of 6.314 billion yuan, with a net profit of 1.838 billion yuan [2][3]. - In Q3 2024, the company reported a revenue of 2.062 billion yuan and a net profit of 597 million yuan, reflecting a year-on-year increase of 1.34% and 8.82%, respectively [2][3]. - The company's gross margin for Q3 2024 was 40.13%, a decrease of 0.57 percentage points year-on-year, while the net profit margin improved by 2.05 percentage points to 28.97% [3]. Research and Development - The R&D expense ratio increased to 4.11% in Q3 2024, up by 1.87 percentage points year-on-year [3]. Market Performance - The company's stock price as of October 30, 2024, was 7.40 yuan, with a market capitalization of approximately 49.12 billion yuan [3][4]. - Over the past 12 months, the company's stock has increased by 7.6%, compared to a 8.5% increase in the CSI 300 index [3]. Earnings Forecast - The report forecasts revenues of 8.65 billion yuan, 9.76 billion yuan, and 10.89 billion yuan for 2024, 2025, and 2026, respectively, with corresponding net profits of 2.313 billion yuan, 2.653 billion yuan, and 2.991 billion yuan [4][7]. - The projected P/E ratios for the next three years are 21.23X, 18.52X, and 16.42X [4][7].